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Abstract
Background: Multidrug-resistant tuberculosis (MDR-TB) is a major threat to global TB control. MDR-TB treatment
regimens typically have a high pill burden, last 20 months or more and often lead to unsatisfactory outcomes.
A 9–11 month regimen with seven antibiotics has shown high success rates among selected MDR-TB patients
in different settings and is conditionally recommended by the World Health Organization.
Methods: We construct a transmission-dynamic model of TB to estimate the likely impact of a shorter MDR-TB
regimen when applied in a low HIV prevalence region of Uzbekistan (Karakalpakstan) with high rates of drug
resistance, good access to diagnostics and a well-established community-based MDR-TB treatment programme
providing treatment to around 400 patients. The model incorporates acquisition of additional drug resistance
and incorrect regimen assignment. It is calibrated to local epidemiology and used to compare the impact of
shorter treatment against four alternative programmatic interventions.
Results: Based on empirical outcomes among MDR-TB patients and assuming no improvement in treatment
success rates, the shorter regimen reduced MDR-TB incidence from 15.2 to 9.7 cases per 100,000 population
per year and MDR-TB mortality from 3.0 to 1.7 deaths per 100,000 per year, achieving comparable or greater
gains than the alternative interventions. No significant increase in the burden of higher levels of resistance was
predicted. Effects are probably conservative given that the regimen is likely to improve success rates.
Conclusions: In addition to benefits to individual patients, we find that shorter MDR-TB treatment regimens
also have the potential to reduce transmission of resistant strains. These findings are in the epidemiological
setting of treatment availability being an important bottleneck due to high numbers of patients being eligible
for treatment, and may differ in other contexts. The high proportion of MDR-TB with additional antibiotic
resistance simulated was not exacerbated by programmatic responses and greater gains may be possible in
contexts where the regimen is more widely applicable.
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Background
Rifampicin-resistant tuberculosis and multidrug-resistant
TB (MDR-TB; resistance to at least rifampicin and iso-
niazid) are among the greatest current threats to global
TB control [1, 2]. An estimated 480,000 incident cases of
MDR-TB occurred in 2014, but only 111,000 were re-
ported to have been started on second-line treatment [3].
Globally, only half of those starting treatment complete it
successfully, with many patients stopping treatment, not
responding or dying. Therefore, about 10% of all incident
MDR-TB cases globally are known to successfully navigate
the complex pathway from presentation to detection
and identification as multidrug-resistant, and subsequently
through the difficult, toxic and costly treatment regimen.
The countries of Eastern Europe and the former Soviet
Union report among the highest proportions of TB pa-
tients presenting with MDR-TB, both among new and
retreatment cases [3]. In Uzbekistan, a former Soviet
Union republic in Central Asia, TB prevalence was esti-
mated at 122 (range, 61–204) per 100,000 population in
2014 [4]. About 7100 MDR-TB cases would be detect-
able among notified pulmonary TB cases, making it one
of the 30 high-burden MDR-TB countries as defined by
the World Health Organization (WHO). A national drug
resistance survey conducted in 2011 found that 23% of
new cases and 62% of previously treated cases had
MDR-TB [5]. These levels varied within the country, and
one region, Karakalpakstan in western Uzbekistan, with
a population of 1.7 million, had the highest ratios (41%
in new and 78% in retreatment cases). Since the early
2000s, Médecins sans Frontières (MSF) has been supporting
the national TB programme of Karakalpakstan to strengthen
TB surveillance, prevention and care. The model of
care considers either inpatient or outpatient treatment,
with a focus on providing early, supported ambulatory
treatment, where possible.
Short-course regimens for MDR-TB (which typically
consist of at least 9 months of fluoroquinolone, ethambutol,
pyrazinamide and clofazimine, supplemented by high-dose
isoniazid, kanamycin and prothionamide in the intensive
phase) have been proposed and implemented in a number
of settings in Africa and Asia [6–9]. Relapse-free treatment
success rates of 84–90% and lower costs than currently rec-
ommended MDR-TB regimens have been reported in se-
lected patient groups.
WHO has recently recommended the use of the shorter
MDR-TB regimen only if patients do not have extrapul-
monary TB, are not pregnant and if all medications from
the shorter regimen are likely to be effective, based on the
patient’s treatment history and the known or presumed re-
sistance profile of the isolate [10, 11]. The efficacy of the
regimen is currently being evaluated in a multicentre ran-
domised controlled trial [12]. While uncertainties remain
around the effectiveness of these regimens in some patient
groups (e.g. children), they have stimulated much interest
given the substantial boost they could provide to program-
matic efforts if results obtained to date could be repro-
duced on a larger scale.
In 2013, MSF, in collaboration with the health au-
thorities, commenced an observational study to meas-
ure the effectiveness of a shorter MDR-TB regimen in
Karakalpakstan [13]. We present a mathematical model to
estimate the likely impact of a 9–11 month MDR-TB regi-
men in Karakalpakstan on rates of disease and death, and
compare this estimate with scenarios where alternative ap-
proaches are used to scale-up TB treatment programmes.
Methods
The model structure is presented in Fig. 1 and the model-
ling approach is described in detail in Additional file 1,
which lists compartment abbreivations (Additional file 1:
Table S1) and parameter values (Additional file 1: Table S2).
The model is based on our previous work [14] and
incorporates a number of aspects that we consider import-
ant to modelling TB epidemiology in regions highly en-
demic for both TB and MDR-TB, including partial vaccine
efficacy (leakiness) [15, 16], declining risk of active disease
with time from infection, reinfection during latency, and ac-
quisition of drug resistance through de novo amplification.
Strains of TB modelled
Our existing model includes both MDR-TB and non-
MDR-TB (henceforward DS-TB), with parameters for
treatment duration and detection rates differing for each
strain (note that a capital “S” indicates model compart-
ments susceptible to infection, while a subscript “s” refers
to antibiotic susceptibility.) While all rifampicin-resistant
TB cases (including mono- and non-MDR-TB poly-
resistant cases) are eligible for a full MDR-TB regimen
[17], this analysis focuses on MDR-TB because rifampi-
cin resistance is highly correlated with MDR-TB in the
setting described [5] (note that the term “strain” does
not necessarily refer to phylogenetically distinct lineages,
but is used henceforward to refer to groups of M. tubercu-
losis organisms differing by drug resistance profile).
In order to consider the impact of programmatic ap-
proaches to improving MDR-TB control on the emer-
gence of drug resistance, a third strain of TB is included
within the model to represent patients ineligible for the
short-course regimen. Henceforward, we use the abbrevi-
ation “XDR-TB” to refer to MDR-TB patients ineligible for
the shorter regimen and “MDR-TB” to refer to patients
with MDR-TB without additional resistance, although
neither term accords directly with the corresponding
microbiological definition. The inclusion of organisms
with additional resistance beyond MDR-TB followed an
approach analogous to that used to model MDR-TB by
comparison to DS-TB, considering the acquisition of
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resistance as a progression (DS-TB→MDR-TB→
XDR-TB). The model assumes that, although higher levels
of resistance initially emerge through non-adherence to
treatment and although a fitness cost is incurred by ad-
vancing resistance, all strains remain transmissible.
Detection and treatment commencement
Separate compartments were used to distinguish the de-
tection of cases of TB from the process of distinguishing
the drug-susceptibility pattern of the infecting strain
(Fig. 1). The first step in the diagnostic pathway consists
of the patient’s presentation to the health system, which
may be patient- or health system-related (e.g. due to false
negatives in the diagnostic algorithm for the diagnosis of
active TB). The model assumes that the rate of detection
of persons with active TB is equal for all strains (moving
from each I compartment to the corresponding linked D
compartments), but that patients with resistant strains can
then be misclassified with regards to their infecting strain
according to the availability of diagnostics able to distin-
guish between MDR- and XDR-TB.
The proportion of individuals correctly identified with
MDR-TB (Dmm ÷ [Dmm +Dms]) is determined by the
availability and sensitivity of first-line drug resistance
testing. This proportion is equal to the proportion of pa-
tients with XDR-TB who are diagnosed as having either
MDR-TB or XDR-TB, as patients with XDR-TB are re-
sistant to rifampicin and isoniazid by definition. Similarly,
active XDR-TB correctly identified as MDR-TB patients
may be correctly classified as XDR-TB depending on the
availability of second-line drug resistance testing, or be in-
correctly identified as MDR-TB (Dxm) if only first-line
drug resistance testing is available.
Patients awaiting treatment pass to the treatment
compartments at a rate determined by the availability of
the regimen they have been allocated. For example, for
DS-TB regimens, this applies to all patients determined
by the health service to have DS-TB (i.e. Dss, Dms and
Dxs, who pass to TIs, Tms and Txs, respectively). Patients
appropriately commencing DS-TB regimens become non-
infectious and ultimately recovered if retained on the
regimen, with a proportion also dying and a proportion
undergoing treatment interruption or failure (hencefor-
ward interruption/failure), returning to Is or Im depending
on whether resistance amplification occurs. Similarly,
patients awaiting appropriate MDR-TB and XDR-TB
regimens transition from detected (Dmm and Dxx) to in-
fectious on treatment (TIm and TIx) to non-infectious
(TNm and TNx) as they progress through treatment.
The proportion of MDR-TB treatment interruption/
failures resulting in resistance amplification to XDR-TB
is assumed to be equal to that for DS-TB interruption/
failures amplifying to MDR-TB. Patients whose strain
has not been correctly identified and are commenced on
an inappropriate treatment regimen have a low (but non-
zero) treatment success rate and a modest reduction in
infectiousness throughout the course of their treatment
(Additional file 1: Table S2).
Model calibration
In liaison with programmatic staff, the model was calibrated
to the reported per capita TB incidence rate for Uzbekistan
in 2015 [4], with secondary priorities, including historical
consistency with TB burden in the region (particularly for
more recent time points) and matching reported prevalence
and mortality rates. MDR-TB was introduced into the
model from 1977, such that it became a significant
Fig. 1 Model structure. Spontaneous recovery for patients in the
detected compartments and all death flows are not depicted. Brown
arrows represent case detection flows, the total of which are set
equal for all strains. Hollow arrows represent treatment commencement
flows, which are determined by the total number of persons awaiting
treatment with that regimen and the availability of the regimen for
each of the three regimens. Individual compartment names are
explained in Additional file 1: Table S1 and summarised as follows: blue
text and s subscript, drug-susceptible TB; red text and m subscript,
multidrug-resistant TB; green text and x subscript, XDR-TB (including also
MDR-TB strains with resistance to fluoroquinolones or second-line
injectable agents). S, susceptible to TB (A and B subscripts refer to
fully susceptible and partially immune, respectively); L, latent infection
(A and B subscripts refer to early and late latent infection, respectively);
I, active TB disease in the community not yet detected; D, detected
(first subscript refers to the actual resistance pattern of the infecting
strain, second subscript refers to the strain thought to be present at
diagnosis); T, on treatment (subscripts are as for D compartments for
those incorrectly diagnosed, while for those correctly diagnosed I
subscript indicates still infectious on appropriate regimen, while N
subscript indicates no longer infectious). For simplicity, the model
assumes no Is patients are incorrectly detected as drug-resistant
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proportion of incident cases through the 1990s, consistent
with its historical emergence. At the time of commence-
ment of interventions in 2015, drug-resistant TB (MDR-TB
or XDR-TB) constituted 23% of circulating strains [5], of
which 29% were XDR-TB.
Next, the increasing availability of conventional MDR-
TB treatment was simulated by scaling up the propor-
tion of patients correctly identified as MDR-TB from
2005 to 2012. Treatment availability was capped at a
maximum of 400 patients simultaneously on MDR-TB
treatment regimens at any given point in time by 2012
(which became the predominant limiting factor around
2012), reflecting the current capacity of the program.
This epidemiological calibration is presented visually in
Additional file 1: Figure S1.
Implementation of intervention and comparators
Table 1 presents the scenarios considered and Fig. 2
illustrates their implementation within the model. All
intervention parameter values were increased sigmoi-
dally from their baseline values in 2015 to reach their
target values in 2017.
Short-course regimens for MDR-TB are imple-
mented by decreasing the time spent in the MDR-TB
treatment compartments (TIm, TNm and Txm) from
24 months to 10 months, as the short-course regimen
can be completed in a minimum of 9 months. Treat-
ment outcome proportions for both standard WHO
and short-course regimens are assumed equal and
parameterised to programmatic data on patient out-
comes. As this is a highly conservative assumption
given the improved treatment outcomes and mainten-
ance of relapse-free survival often reported with the
short-course regimen, simulations were repeated with
an increase in treatment success rates to 87.9% [6].
Four comparator interventions were developed that
modify other model parameters by a similar magni-
tude, are programmatically feasible and supported by
evidence of efficacy. These scenarios are intended to
put the magnitude of the response to the short-
course regimen in context, rather than to definitively
estimate the reduction in disease burden achievable
by scaling up alternative programs.
Outcomes
The main outcomes of interest resulting from the inter-
vention and comparators are MDR-TB strain indicators
Table 1 Description of scenarios
Scenario Programmatic implementation and evidence Model implementation
1. Baseline programmatic conditions
continued
All 2014 programmatic parameters remain unchanged
(including 24 month duration of MDR-TB regimen and
400 treatment places available at any one time being the
limiting factor for treatment commencement in 2014)
2A. Short-course MDR-TB regimen Change from standard WHO regimen to
short-course regimen [6–9]
Total period of time on treatment for MDR-TB regimens
decreases from a mean of 24 months to 10 months
(with treatment places remaining capped at 400)
2B. Short-course MDR-TB regimen
with improved outcomes
As for short-course regimen, with improvement
in treatment outcomes [6]
Treatment outcomes improve to a treatment success
rate of 87.9% (with ratio of deaths to defaults under
treatment unchanged), in addition to changes modelled
under short-course regimen scenario above
3. Decreased delays to detection for
all forms of TB (first comparator)
Active or intensified case finding halves the
period of time to first presentation from baseline
value [28, 29]
Time from disease onset to correct identification of
patients as having active TB halves (with no change to
the proportion correctly identified as to their infecting
strain)
4. Improved MDR-TB treatment
outcomes (second comparator)
Social support for all patients on treatment
halves the proportion of outcomes resulting in
interruption/failure or death [30]
Proportion of patients interrupting/failing or dying on
treatment halves (with treatment success proportion
increasing to 1 – [1 – previous treatment success
proportion] ÷ 2)
5. Improved MDR-TB identification
(third comparator)
Halve the number of health facilities without
access to drug-susceptibility testing (e.g. Xpert
MTB/RIF), thereby halving the proportion of
patients not recognised as MDR-TB at
presentation [31, 32]
Proportion of patients with MDR-TB who are incorrectly
diagnosed as having DS-TB halves (with correct diagnosis
proportion increasing to 1 – [1 – previous correct
identification proportion] ÷ 2)
6. Increased MDR-TB treatment
availability (fourth comparator)
Increased resources doubles the number of
patients that can be simultaneously treated
Increase number of MDR-TB treatment places available
to 800 (with DS-TB and XDR-TB treatment capacity
unchanged)
DS-TB Drug-susceptible tuberculosis, MDR-TB Multidrug-resistant tuberculosis, TB Tuberculosis, WHO World Health Organization, XDR-TB Extensively
drug-resistant tuberculosis
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(including absolute and proportionate incidence, preva-
lence and mortality).
Sensitivity analyses
To better understand the effects of programmatic re-
sponses implemented simultaneously, we undertook a
sensitivity analysis using Latin Hypercube Sampling to
simultaneously vary the key parameters used in inter-
vention implementation. Calibration remains un-
changed, but the parameters used to simulate the
alternative interventions from 2015 onwards are var-
ied across plausible ranges divided into 10,000 equal
sub-intervals.
An alternative set of analyses are presented to consider
the programmatic impact of the same scenarios if the
proportionate burden of MDR-TB has been underesti-
mated, as could be inferred from the higher proportions
of MDR-TB observed in Karakalpakstan in the 2011
drug resistance survey (although not statistically signifi-
cantly different from the national estimate).
Fig. 2 Implementation of main intervention and comparators. Model of the implementation of short-course MDR-TB and of the four comparator
programmatic interventions. Increased flows highlighted by thick purple arrows, with indirect effects indicated through dashed purple arrows. For
Scenario 4, the flows that are decreased are illustrated with thin purple arrows. Reinfection omitted
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Results
Scenarios
Figure 3 and Table 2 present the results of the seven
simulated Scenarios (baseline, two short-course MDR-
TB regimen assumptions and four comparator interven-
tions). Under the baseline Scenario, the resistant strains
contribute an increasing proportion of disease over the
10 years to 2025, as their lower relative fitness is more
than offset by their comparative advantages in diagnosis
and treatment outcomes.
Shortening the MDR-TB regimen duration has the
greatest impact on MDR-TB burden of all interventions
and has a significant effect on the overall TB burden in
the region. A short-lived increase in TB and MDR-TB
deaths is associated with the short-course regimen inter-
vention. This results from a more rapid time to reaching
the same outcomes (including death) than under the
baseline conventional MDR-TB regimen scenario, and is
not observed under the short-course with improved out-
comes scenario. Under this scenario, some of the avail-
able treatment capacity (400 MDR-TB treatment places)
is not filled due to faster throughput of patients.
Both decreased delays to TB detection and improved
MDR-TB identification have no positive effect on
MDR-TB indicators due to the absence of treatment
availability for the increased number of identified pa-
tients under the programmatic conditions simulated.
The impact of these two interventions on overall TB
burden is also relatively small in this high MDR-TB
burden setting. The greatest effect of improved MDR-
TB treatment outcomes is on MDR-TB mortality, al-
though its impact is small. Increased MDR-TB treat-
ment availability results in improvements in MDR-TB
burden broadly comparable to the change in regimen
duration. None of the interventions simulated has a
marked effect on absolute XDR-TB burden, with no
significant increase in amplification from MDR-TB to
XDR-TB observed through more rapid throughput of
MDR-TB patients.
Additional file 1: Figure S2 illustrates the mechanisms
of these interventions, indicating that doubling treatment
places and decreasing regimen duration both result in
treatment availability not being the limiting factor in
patients starting treatment.
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1. Baseline programmatic conditions continued
2A. Short course MDR-TB regimen
2B. Short course regimen with improved outcomes
3. Decreased delays to TB detection
4. Improved MDR-TB treatment outcomes
5. Improved MDR-TB identification
6. Increased MDR-TB treatment availability
Fig. 3 Scenario outcomes. Strains are presented by columns of panels and disease burden outcomes are presented by rows. Legend for all plots
is presented in the lower left panel
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Table 2 Scenario results and percentage differences from baseline scenario in 2025
1. Baseline 2A. Short-course
regimen
2B. Short-course, improved
outcomes
3. Decreased delays
to detection
4. Improved MDR-TB
treatment outcomes
5. Improved MDR-TB
identification
6. Increased MDR-TB
treatment availability
Total incidencea 77.2 71.1 69.4 65.6 73.9 80.2 73.3
% change −8.0% −10.2% −15.0% −4.4% +3.8% −5.1%
Total prevalenceb 105.7 83.6 79.0 89.6 97.7 111.8 99.5
% change −20.9% −25.2% −15.2% −7.5% +5.8% −5.8%
Total mortalitya 10.4 8.7 7.7 8.7 9.1 11.1 9.3
% change −16.6% −25.9% −16.6% −12.7% +7.3% −10.2%
MDR-TB incidencea 15.2 9.7 8.7 14.6 12.2 18.2 11.2
% change −36.0% −42.8% −4.3% −19.6% +19.8% −26.4%
MDR-TB prevalenceb 63.0 40.8 36.1 61.6 55.0 69.2 56.7
% change −35.2% −42.6% −2.2% −12.7% +9.9% −9.9%
MDR-TB mortalitya 3.0 1.7 1.0 2.8 1.9 3.8 1.9
% change −43.9% −67.2% −6.2% −38.2% +27.5% −37.1%
Proportion of incident cases MDR-TB 34.8 28.9 27.1 40.1 31.7 37.3 31.2
% change −16.9% −22.1% +15.1% −8.9% +7.1% −10.5%
XDR-TB incidencea 11.7 10.8 10.1 11.7 11.2 11.7 11.6
% change −7.2% −13.3% +0.5% −4.2% −0.1% −0.4%
XDR-TB prevalenceb 29.8 26.6 24.5 30.0 28.5 29.3 30.2
% change −10.8% −17.7% +0.5% −4.4% −1.6% +1.2%
XDR-TB mortalitya 4.0 3.6 3.3 4.1 3.9 4.0 4.1
% change −10.5% 17.2% +0.5% −4.3% −1.6% +1.2%
Proportion of incident cases XDR-TB 15.1 15.2 14.6 17.9 15.1 14.6 15.9
% change +0.8% −3.5% +18.2% +0.1% −3.8% +5.0%
aPer 100,000 population per year
bPer 100,000 population
MDR-TB Multidrug-resistant tuberculosis, XDR-TB Extensively drug-resistant tuberculosis
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Sensitivity and alternative analyses
The sensitivity analysis, which considers multiple programs
implemented simultaneously, shows that several interven-
tions have the potential to be synergistic (Additional file 1:
Figures S4 and S5). For example, reducing MDR-TB mis-
classification can significantly reduce disease burden if
combined with interventions that ensure that treatment is
available to these patients once identified as MDR-TB. As
decreasing time to presentation has a greater effect on
DS-TB than MDR-TB, its effects on the absolute and
relative burden of MDR-TB are opposite.
The alternative analysis under more pessimistic assump-
tions regarding the burden of MDR-TB (Additional file 1:
Figure S3) further highlights the importance of increasing
treatment availability or reducing regimen duration in im-
proving MDR-TB burden in Karakalpakstan.
Discussion
We find that implementing a 10-month treatment regi-
men for MDR-TB is among the most effective means for
reducing the impact of this dangerous threat to global
TB control in Karakalpakstan, a region with high rates
of drug resistance among TB patients. The more rapid
throughput of patients leads to an initial transient in-
crease in mortality under the conservative assumption of
unchanged treatment outcomes, although this is not a
programmatically significant effect and is followed by a
quick recovery and consistent decline in disease rates
thereafter. Our model did not predict that wider use of
the shorter MDR-TB regimen would increase the acqui-
sition of additional drug resistance. The comparator
intervention that led to reductions in MDR-TB disease
burden most similar to expansion of the short-course
regimen was doubling of MDR-TB treatment availability,
while the other comparators were less effective. More-
over, synergistic effects could be expected if wider use of
shorter MDR-TB regimens is combined with improved
case detection.
Our first modelling study of TB transmission aimed to
establish a flexible approach to simulating TB transmis-
sion dynamics in highly endemic settings within the
framework of a deterministic compartmental model, but
assumed regimen duration to be fixed for each strain. In
this earlier work, we found that MDR-TB became the
dominant strain at model equilibrium even in the pres-
ence of significant fitness costs, which is attributable to
both lower rates of case detection and differences in
progression through treatment [14]. In this study, we
consider the issues surrounding the diagnostic process
in greater detail, distinguishing detection of active TB
from the process of determining the extent of drug resist-
ance in the infecting organism and subsequent progress
through the treatment regimen. The relative importance
of each of these processes is likely to be setting-dependent
and programs may act synergistically, as bottlenecks will
exist at different points in the complex journey from ac-
tive disease through to treatment completion.
Our conclusions depend on a number of model assump-
tions and the local TB epidemiology simulated. In particu-
lar, our modelling of a treatment program close to capacity
explains the lack of effect observed from improved detec-
tion of TB cases and improved identification of MDR-TB
patients from those detected. Additional file 1: Figure S2
shows that the reason for the relative ineffectiveness of
most comparator interventions (all except increasing avail-
ability of MDR-TB treatment) is that they do nothing to re-
lieve the bottleneck of treatment availability, such that
numbers of patients awaiting treatment increase rapidly
over the intervention period. Although there is no formal
limit on MDR-TB treatment availability in Karakalpakstan,
we consider expansion of the treatment program to
manage the markedly increased patient load to be a
programmatic intervention. As expected, doubling treat-
ment availability and decreasing treatment time 2.4-fold
had comparable effects on incidence and mortality, al-
though the shorter treatment time had a greater effect on
prevalence, as patients are considered prevalent cases until
treatment is completed. The small increase in MDR-TB
burden through improved detection is due to patients
transitioning from being on inappropriate treatment for
DS-TB (which is considered to have a partial therapeutic
effect) to identified but awaiting treatment (and so un-
treated). Under- or over-estimation of the absolute or rela-
tive burden of each of the TB strains in the Province are
likely to affect our conclusions, although only a markedly
lower absolute burden of MDR-TB is likely to result in
significant attenuation of the benefits from the shorter
regimen. Given the complexity of the baseline dynamics
simulated, we focused on programmatic parameters in
our sensitivity analysis, rather than exploring variations
of all parameters.
Our findings are likely to be generalisable to a number
of other contexts in which treatment capacity is an im-
portant constraint, as the shorter regimen can be used
in HIV-positive and paediatric populations. However, the
programmatic situation is a key determinant of the regi-
men’s likely impact, as other factors may limit treatment
commencement. For example, if MDR-TB treatment
capacity is available but access to drug-susceptibility test-
ing (DST) is limited and many patients are on incorrect
regimens, improving access to DST is likely to compare
more favourably to other interventions. Such situations
may exist in contexts where intense community transmis-
sion of MDR-TB occurs, but DST is reserved for retreat-
ment cases only. Alternatively, if extensive pre-health
system delays to presentation are important in limiting
the rate at which MDR-TB patients commence treatment,
active case finding is likely to have a greater effect in
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reducing the burden of disease attributable to this strain.
Therefore, in these situations, the shorter regimen may
compare less favourably to these two interventions. Last,
if poor treatment outcomes are reported programmatic-
ally, the shorter regimen may have a significant impact if
improved treatment outcomes can be achieved, rather
than by relieving the bottleneck to treatment com-
mencement. Synergistic effects were observed in this
study, which is understandable as both the shorter regi-
men and increased treatment capacity led to unfilled
treatment capacity, which could be used if more pa-
tients with MDR-TB were detected by the health sys-
tem and/or correctly classified as MDR-TB (Additional
file 1: Figures S2, S4, S5).
A previous programmatic application of a similar model
to Western Province of Papua New Guinea found a
smaller impact of the short-course regimen [16]. However,
in this earlier study, we considered treatment commence-
ment to be dependent on the rate at which MDR-TB
patients were detected, but independent of treatment
availability. We also previously considered an extended
period of hospitalisation to be necessary for implementa-
tion of the shorter regimen, due to the number of drugs
employed during the intensive phase of treatment. Al-
though this consideration is not explicitly modelled
here, the community-based approach to treatment cur-
rently employed in Karakalpakstan would make scale-up
of treatment (e.g. Scenario 6) less resource-intensive and
more feasible than in settings where hospitalisation is
deemed essential throughout the intensive phase.
We do not present an economic analysis and the com-
parator interventions are not intended to be equivalent
in terms of resource consumption or expense. However,
several may be considerably more difficult to implement
and many of the resources already in place to provide the
standard WHO regimen could be adapted to short-course
treatment. In fact, the short-course intervention is likely
to be significantly cost-saving, as we estimate the expense
of the short-course regimen at around 760 Euros in
Karakalpakstan by comparison to over 3000 Euros for
the standard regimen (personal communication MSF),
which is consistent with estimates from elsewhere [10, 18].
Therefore, even under scenarios that achieve a higher
throughput of patients as a result of faster treatment
completion, the short-course intervention should be
cost saving due to its lower cost per unit time on treat-
ment. By contrast, for programs such as active case find-
ing, improved MDR-TB identification, patient monitoring
for response to treatment and support for adverse effects,
and increased treatment availability, significant additional
resources are likely to be required.
The short-course regimen we consider is based on
analysis of sequential cohorts of patients enrolled into
treatment in Bangladesh and elsewhere [6–9]. The study
and subsequent follow-up has demonstrated favourable
outcomes sustained after treatment completion without
significant amplification of resistance [9]. There has been
debate over whether a regimen based on this form of
evidence, rather than the gold standard of the rando-
mised controlled trial, should be accepted for program-
matic use. Therefore, a multi-centre, non-inferiority
randomised controlled trial has been initiated to better
determine the efficacy of safety of the regimen [12]. Such
evidence will be of great use in determining the extent
and speed with which such regimens should be adopted,
particularly given that the standard regimens are based
on very low quality evidence [19] and that meta-analyses
of standardised regimens estimate treatment success
rates around 50% (when including patients ineligible for
shorter regimens) [20].
The recent WHO guidelines provide a conditional rec-
ommendation supporting the use of the shorter regimen
in the context of further research, although the broader
epidemiological impact of the regimen has not yet been
observed. Modelling the likely effect of such a program-
matic change is important in this context. This study aims
to realistically simulate the introduction of short-course
regimens for a similar patient group to that recommended
for treatment by the WHO guidelines [10].
Local patterns of drug resistance are also an important
consideration, as it is important to limit treatment to pa-
tients infected with strains susceptible to the constitu-
ents of the regimen as much as possible, to avoid further
exacerbating drug resistance problems. Although evidence
for the effectiveness of short-course MDR-TB regimens is
now emerging from a range of settings [7], our study is
not intended to determine the regimen’s efficacy, but ra-
ther to estimate likely improvements in MDR-TB control
through shortening treatment duration.
Although new agents are now available for the treat-
ment of MDR-TB [21, 22], these are largely intended to
strengthen conventional MDR-TB regimens [23]. More
important than the development of single agents is the
formulation of new regimens to reduce treatment dur-
ation at the programmatic level. Therefore, trials of new
shorter regimens, such as STAND (Shortening Treatment
by Advancing Novel Drugs, NCT02342886), Practecal
and Nix-TB, hold promise for improvements in TB
treatment effectiveness [24–26]. Moreover, STREAM II
(The Evaluation of a Standard Treatment Regimen of
Anti-Tuberculosis Drugs for Patients with Multidrug-
Resistant Tuberculosis, ISRCTN18148631), which con-
siders several short-course regimens, includes a treatment
arm in which injectable agents are avoided entirely
[27]. Although proving the efficacy of these regimens
is essential, it is also important to demonstrate that
programmatic benefits are achievable to argue for their
introduction.
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Conclusions
We find that short-course regimens hold substantial prom-
ise in reducing the overall burden of disease and death due
to MDR-TB in Karakalpakstan and have the potential to be
a major weapon in the fight against this strain. The context
in which the regimen is introduced is a key determinant of
its likely impact and changing to the shorter regimen is
likely to be most beneficial in settings where treatment
capacity is an important programmatic consideration. Im-
plementation of the shorter regimen did not lead to a sig-
nificant increase in the prevalence of more resistant strains
(e.g. XDR-TB), although such strains limited the extent to
which the shorter regimen could be applied.
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